SPONSOR
Fujian Akeylink Biotechnology Co., Ltd.
Total Trials
2
Recruiting
2
Phases
Phase 3, Phase 2
Fujian Akeylink Biotechnology Co., Ltd. is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Chronic Hepatitis b, Chronic Hepatitis B.
The trial portfolio spans Phase 3, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Fujian Akeylink Biotechnology Co., Ltd.
How many clinical trials has Fujian Akeylink Biotechnology Co., Ltd. sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Fujian Akeylink Biotechnology Co., Ltd., of which 2 are actively recruiting participants. These trials cover conditions including Chronic Hepatitis b, Chronic Hepatitis B. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Fujian Akeylink Biotechnology Co., Ltd. research focus on?
Fujian Akeylink Biotechnology Co., Ltd. clinical trials span Chronic Hepatitis b, Chronic Hepatitis B. The research pipeline includes Phase 3, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Fujian Akeylink Biotechnology Co., Ltd. clinical trial?
To participate in a Fujian Akeylink Biotechnology Co., Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Fujian Akeylink Biotechnology Co., Ltd. trials with current recruitment status updated daily.
Clinical Trials by Fujian Akeylink Biotechnology Co., Ltd.
NCT07090759 Phase 3
Recruiting
To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment
Chronic Hepatitis b
NCT06263959 Phase 2
Recruiting
A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B
Chronic Hepatitis B
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology